Targeting the nuclear receptor-cofactor interaction

Nuclear Receptors as Drug Targets

Volumn 39, Issue , 2008, Pages 25-45

  Vaz, Belen ^a   Möcklinghoff, Sabine ^a   Brunsveld, Luc ^a  

^a CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

Author keywords

Coactivators; Cofactors; Inhibitors of protein protein interactions; LXXLL motif; Nuclear receptors; Peptides; Protein protein interactions

Indexed keywords

PEPTIDES;

COACTIVATORS; COFACTORS; LXXLL MOTIFS; NUCLEAR RECEPTORS; PROTEIN-PROTEIN INTERACTIONS;

PROTEINS;

EID: 84908243878     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623297.ch2     Document Type: Chapter

References (68)

1. Lonard, D.M. and O'Malley, B.W. (2005) Expanding functional diversity of the coactivators. Trends in Biochemical Sciences, 30, 126-132.
2. Smith, C.L. and O'Malley, B.W. (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews, 25, 45-71.
3. Taplin, M.E., Bubley, G.J., Ko, Y.J., Small, E.J., Upton, M., Rajeshkumar, B. and Balk, S.P. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Research, 59, 2511-2515.
4. Folkertsma, S., van Noort, P.I., Brandt, R.F.J., Bettler, E., Vriend, G. and de Vlieg, J. (2005) The nuclear receptor ligandbinding domain: a family-based structure analysis. Current Medicinal Chemistry, 12, 1001-1016.
5. Lonard, D.M. and O'Malley, B.W. (2006) The expanding cosmos of nuclear receptor coactivators. Cell, 125, 411-414.
6. McInerney, E.M., Rose, D.W., Flynn, S.E., Westin, S., Mullen, T.M., Krones, A., Inostroza, J., Torchia, J., Nolte, R.T., Assa-Munt, N., Milburn, M.V., Glass, C.K. and Rosenfeld, M.G. (1998) Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes and Development, 12, 3357-3368.
7. Iannone, M.A., Simmons, C.A., Kadwell, S.H., Svoboda, D.L., Vanderwall, D.E., Deng, S.J., Consler, T.G., Shearin, J., Gray, J.G. and Pearce, K.H. (2004) Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Molecular Endocrinology, 18, 1064-1081.
8. Nettles, K.W. and Greene, G.L. (2005) Ligand control of coregulator recruitment to nuclear receptors. Annual Review of Physiology, 67, 309-333.
9. Rodriguez, A.L., Tamrazi, A., Collins, M.L. and Katzenellenbogen, J.A. (2004) Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor α coactivator binding. Journal of Medicinal Chemistry, 47, 600-611.
10. Zwart, W., Griekspoor, A., Berno, V., Lakeman, K., Jalink, K., Mancini, M., Neefjes, J. and Michalides, R. (2007) PKA-induced resistance to tamoxifen is associated with an altered, orientation of ERα towards co-activator SRC1. The EMBO Journal, 26, 3534-3544.
11. Bourguet, W., Germain, P. and Gronemeyer, H. (2000) Nuclear receptor ligand-binding domains threedimensional structures, molecular interactions and pharmacological implications. Trends in Pharmacological Sciences, 21, 381-388.
12. Estebanez-Perpina, E., Moore, J.M.R., Mar, E., Delgado-Rodrigues, E., Nguyen, P., Baxter, J.D., Buehrer, B.M., Webb, P., Fletterick, R.J. and Guy, R.K. (2005) The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. The Journal of Biological Chemistry, 280, 8060-8068.
13. Shiau, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard, D.A. and Greene, G.L. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95, 927-937.
14. Kuiper, G.G.J.M., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S. and Gustafsson, J.A. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology, 138, 863-870.
15. Mosselman, S., Polman, J. and Dijkema, R. (1996) ER β: Identification and characterization of a novel human estrogen receptor. FEBS Letters, 392, 49-53.
16. Norris, J.D., Paige, L.A., Christensen, D.J., Chang, C.Y., Huacani, M.R., Fan, D.J., Hamilton, P.T., Fowlkes, D.M. and McDonnell, D.P. (1999) Peptide antagonists of the human estrogen receptor. Science, 285, 744-746.
17. Paige, L.A., Christensen, D.J., Gron, H., Norris, J.D., Gottlin, E.B., Padilla, K.M., Chang, C.Y., Ballas, L.M., Hamilton, P.T., McDonnell, D.P. and Fowlkes, D.M. (1999) Estrogen receptor (ER) modulators each induce distinct conformational, changes in ER α and ER β. Proceedings of the National Academy of Sciences of the United States of America, 96, 3999-4004.
18. Chang, C.Y., Norris, J.D., Gron, H., Paige, L.A., Hamilton, P.T., Kenan, D.J., Fowlkes, D. and McDonnell, D.P. (1999) Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors α and β. Molecular and Cellular Biology, 19, 8226-8239.
19. Wurtz, J.M., Bourguet, W., Renaud, J.P., Vivat, V., Chambon, P., Moras, D. and Gronemeyer, H. (1996) A canonical structure for the ligand-binding domain of nuclear receptors. Nature Structural Biology, 3, 87-94.
20. Heldring, N., Nilsson, M., Buehrer, B., Treuter, E. and Gustafsson, J.A. (2004) Identification of tamoxifen-induced coregulator interaction surfaces within the ligand-binding domain of estrogen receptors. Molecular and Cellular Biology, 24, 3445-3459.
21. Kong, E.H., Heldring, N., Gustafsson, J.A., Treuter, E., Hubbard, R.E. and Pike, A.C.W. (2005) Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America, 102, 3593-3598.
22. Wang, S., Zhang, C., Nordeen, S.K. and Shapiro, D.J. (2007) In vitro fluorescence anisotropy analysis of the interaction of full-length SRC1a with estrogen receptors α and β supports an active displacement model for coregulator utilization. The Journal of Biological Chemistry, 282, 2765-2775.
23. 2-terminal interaction with the ligand binding domain of the androgen receptor. The Journal of Biological Chemistry, 275, 22986-22994.
24. 2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. The Journal of Biological Chemistry, 273, 92-101.
25. Hodgson, M.C., Astapova, I., Cheng, S., Lee, L.J., Verhoeven, M.C., Choi, E., Balk, S.P. and Hollenberg, A.N. (2005) The androgen receptor recruits nuclear receptor corepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. The Journal of Biological Chemistry, 280, 6511-6519.
26. van Royen, M.E., Cunha, S.M., Brink, M.C., Mattern, K.A., Nigg, A.L., Dubbink, H.J., Verschure, P.J., Trapman, J. and Houtsmuller, A.B. (2007) Compartmentalization of androgen receptor protein-protein interactions in living cells. The Journal of Cell Biology, 177, 63-72.
27. 2- and COOH-terminal interaction. The Journal of Biological Chemistry, 277, 25631-25639.
28. Fujimoto, N., Yeh, S.Y., Kang, H.Y., Inui, S., Chang, H.C., Mizokami, A. and Chang, C.S. (1999) Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. The Journal of Biological Chemistry, 274, 8316-8321.
29. Kang, H.Y., Yeh, S.Y., Fujimoto, N. and Chang, C.S. (1999) Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. The Journal of Biological Chemistry, 274, 8570-8576.
30. Yeh, S.Y. and Chang, C.S. (1996) Cloning and characterization of a specific coactivator, ARA(70), for the androgen receptor in human prostate cells. Proceedings of the National Academy of Sciences of the United States of America, 93, 5517-5521.
31. He, B., Minges, J.T., Lee, L.W. and Wilson, E.M. (2002) The FXXLF motif mediates androgen receptor-specific interactions with coregulators. The Journal of Biological Chemistry, 277, 10226-10235.
32. Hu, Y.C., Yeh, S.Y., Yeh, S.D., Sampson, E.R., Huang, J.T., Li, P., Hsu, C.L., Ting, H.J., Lin, H.K., Wang, L., Kim, E., Ni, J. and Chang, C.S. (2004) Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. The Journal of Biological Chemistry, 279, 33438-33446.
33. Rahman, M.M., Miyamoto, H., Takatera, H., Yeh, S.Y., Altuwaijri, S. and Chang, C.S. (2003) Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. The Journal of Biological Chemistry, 278, 19619-19626.
34. Rahman, M.M., Miyamoto, H., Lardy, H. and Chang, C. (2003) Inactivation of androgen receptor coregulator ARA55 inhibits androgen, receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 5124-5129.
35. van de Wijngaart, D.J., van Royen, M.E., Hersmus, R., Pike, A.C.W., Houtsmuller, A.B., Jenster, G., Trapman, J. and Dubbink, H.J. (2006) Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain. The Journal of Biological Chemistry, 281, 19407-19416.
36. Hur, E., Pfaff, S.J., Payne, E.S., Gron, H., Buehrer, B.M. and Fletterick, R.J. (2004) Recognition and accommodation at the androgen receptor coactivator binding interface. Plos Biology, 2, 1303-1312.
37. Hsu, C.L., Chen, Y.L., Yeh, S.Y., Ting, H.J., Hu, Y.C., Lin, H., Wang, X. and Chang, C.S. (2003) The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W) XXL(F/W) and FXXLY new signature motifs. The Journal of Biological Chemistry, 278, 23691-23698.
38. Chang, C.Y., Abdo, J., Hartney, T. and McDonnell, D.P. (2005) Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Molecular Endocrinology, 19, 2478-2490.
39. He, B., Gampe, R.T., Kole, A.J., Hnat, A.T., Stanley, T.B., An, G., Stewart, E.L., Kalman, R.I., Minges, J.T. and Wilson, E.M. (2004) Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Molecular Cell, 16, 425-438.
40. He, B., Gampe, R.T., Hnat, A.T., Faggart, J.L., Minges, J.T., French, F.S. and Wilson, E.M. (2006) Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity. The Journal of Biological Chemistry, 281, 6648-6663.
41. Gregory, C.W., He, B., Johnson, R.T., Ford, O.H., Mohler, J.L., French, F.S. and Wilson, E.M. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Research, 61, 4315-4319.
42. Taplin, M.E., Bubley, G.J., Shuster, T.D., Frantz, M.E., Spooner, A.E., Ogata, G.K., Keer, H.N. and Balk, S.P. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate-cancer. The New England Journal of Medicine, 332, 1393-1398.
43. Veldscholte, J., Berrevoets, C.A., Risstalpers, C., Kuiper, G.G.J.M., Jenster, G., Trapman, J., Brinkmann, A.O. and Mulder, E. (1992) The androgen receptor in lncap cells contains a mutation in the ligand-binding domain which affects steroid binding characteristics and response to antiandrogens. The Journal of Steroid Biochemistry and Molecular Biology, 41, 665-669.
44. Veldscholte, J., Berrevoets, C.A., Brinkmann, A.O., Grootegoed, J.A. and Mulder, E. (1992) Antiandrogens and the mutated androgen receptor of Lncap Cells - differential-effects on binding-affinity, heat-shock protein-interaction, and transcription activation. Biochemistry, 31, 2393-2399.
45. Langley, E., Zhou, Z.X. and Wilson, E.M. (1995) Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. The Journal of Biological Chemistry, 270, 29983-29990.
46. Veldscholte, J., Risstalpers, C., Kuiper, G.G.J.M., Jenster, G., Berrevoets, C., Claassen, E., Vanrooij, H.C.J., Trapman, J., Brinkmann, A.O. and Mulder, E. (1990) A mutation in the ligand-binding domain of the androgen receptor of human lncap cells affects steroid binding characteristics and response to anti-androgens. Biochemical and Biophysical Research Communications, 173, 534-540.
47. Ozers, M.S., Marks, B.D., Gowda, K., Kupcho, K.R., Ervin, K.M., De Rosier, T., Qadir, N., Eliason, H.C., Riddle, S.M. and Shekhani, M.S. (2007) The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wildtype androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry, 46, 683-695.
48. Alen, P., Claessens, F., Verhoeven, G., Rombauts, W. and Peeters, B. (1999) The androgen receptor amino-terminal domain plays a key role in p160 coactivatorstimulated gene transcription. Molecular and Cellular Biology, 19, 6085-6097.
49. 2-terminal domain. The Journal of Biological Chemistry, 274, 37219-37225.
50. He, B. and Wilson, E.A. (2003) Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. Molecular and Cellular Biology, 23, 2135-2150.
51. Slagsvold, T., Kraus, I., Bentzen, T., Palvimo, J. and Saatcioglu, F. (2000) Mutational analysis of the androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic differences of conserved residues compared with other nuclear receptors. Molecular Endocrinology, 14, 1603-1617.
52. Bapat, A.R. and Frail, D.E. (2003) Fulllength estrogen receptor α and its ligand-binding domain adopt different conformations upon binding ligand. The Journal of Steroid Biochemistry and Molecular Biology, 86, 143-149.
53. Chang, C.Y. and McDonnell, D.P. (2002) Evaluation of ligand-dependent changes in AR structure using peptide probes. Molecular Endocrinology, 16, 647-660.
54. Steketee, K., Berrevoets, C.A., Dubbink, H.J., Doesburg, P., Hersmus, R., Brinkmann, A.O. and Trapman, J. (2002) Amino acids 3-13 and amino acids in and flanking the (23)FxxLF(27) motif modulate the interaction between the N-terminal and ligand-binding domain of the androgen receptor. European Journal of Biochemistry, 269, 5780-5791.
55. Dubbink, H.J., Hersmus, R., Pike, A.C.W., Molier, M., Brinkmann, A.O., Jenster, G. and Trapman, J. (2006) Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping. Molecular Endocrinology, 20, 1742-1755.
56. Guy, R.K., Baxter, J.D., Darimont, B., Feng, W., Fletterick, R.J., Kushner, P.J. and Wagner, R.L. PCT/US 2001/20969 [WO 2002/02488].
57. Geistlinger, T.R. and Guy, R.K. (2003) Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. Journal of the American Chemical Society, 125, 6852-6853.
58. Geistlinger, T.R., McReynolds, A.C. and Guy, R.K. (2004) Ligand-selective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms. Chemistry & Biology, 11, 273-281.
59. Northrop, J.P., Nguyen, D., Piplani, S., Olivan, S.E., Kwan, S.T.S., Go, N.F., Hart, C.P. and Schatz, P.J. (2000) Selection of estrogen receptor β- and thyroid hormone receptor β-specific coactivator-mimetic peptides using recombinant peptide libraries. Molecular Endocrinology, 14, 605-622.
60. Leduc, A.M., Trent, J.O., Wittliff, J.L., Bramlett, K.S., Briggs, S.L., Chirgadze, N.Y., Wang, Y., Burris, T.P. and Spatola, A.F. (2003) Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proceedings of the National Academy of Sciences of the United States of America, 100, 11273-11278.
61. Galande, A.K., Bramlett, K.S., Trent, J.O., Burris, T.P., Wittliff, J.L. and Spatola, A.F. (2005) Potent inhibitors of LXXLL-based protein-protein interactions. Chembiochem: A European Journal of Chemical Biology, 6, 1991-1998.
62. Galande, A.K., Bramlett, K.S., Burris, T.P., Wittliff, J.L. and Spatola, A.F. (2004) Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions. The Journal of Peptide Research, 63, 297-302.
63. Fletterick, R.J., Estebanez-Perpina, E., Hur, E., Pfaff, S.J. and Buehrer, B.M. 10/705,165 [US 2005/0202440].
64. Shao, D.L., Berrodin, T.J., Manas, E., Hauze, D., Powers, R., Bapat, A., Gonder, D.I., Winneker, R.C. and Frail, D.E. (2004) Identification of novel estrogen receptor α antagonists. The Journal of Steroid Biochemistry and Molecular Biology, 88, 351-360.
65. Davis, J.M., Tsou, L.K. and Hamilton, A.D. (2007) Synthetic non-peptide mimetics of α-helices. Chemical Society Reviews, 36, 326-334.
66. Becerril, J. and Hamilton, A.D. (2007) Helix mimetics as inhibitors of the interactions of the estrogen receptor with coactivator peptides. Angewandte Chemie, 119, 4555-4557.
67. Wang, Y., Chirgadze, N.Y., Briggs, S.L., Khan, S., Jensen, E.V. and Burris, T.P. (2006) A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor β. Proceedings of the National Academy of Sciences of the United States of America, 103, 9908-9911.
68. Arnold, L.A., Estebanez-Perpina, E., Togashi, M., Jouravel, N., Shelat, A., McReynolds, A.C., Mar, E., Nguyen, P., Baxter, J.D., Fletterick, R.J., Webb, P. and Guy, R.K. (2005) Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. The Journal of Biological Chemistry, 280, 43048-43055.